Hematopoietic Stem Cells clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 12 years and up
The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.
Los Angeles, California and other locations